Pascal and Francis Bibliographic Databases

Help

Permanent link : http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13512079

Export

Selection :

Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone

Author
SARRIS, Andreas H; YUNFANG JIANG; TSIMBERIDOU, Apostolia M; THOMAIDES, Athanasios; RASSIDAKIS, George Z; FORD, Richard J; MEDEIROS, L. Jeffrey; CABANILLAS, Fernando; MCLAUGHLIN, Peter
Department of Lymphoma and Myeloma, and the Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Issue title
Current and ongoing clinical development of immunotherapy in B-cell malignancies
Author (monograph)
ROSEN, Steven T (Editor)1
[1] Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Robert H. Lurie Comprehensive Center, Chicago, IL, United States
Source

Seminars in oncology. 2002, Vol 29, Num 1, pp 48-55 ; SUP2 ; ref : 30 ref

CODEN
SOLGAV
ISSN
0093-7754
Scientific domain
Medical oncology
Publisher
Elsevier, Philadelphia, PA
Publication country
United States
Document type
Article
Language
English
Keyword (fr)
Agent alkylant Anthraquinone dérivé Anticancéreux Anticorps monoclonal Anticytokine Antimétabolite Association médicamenteuse Chimiothérapie Corticostéroïde Dexaméthasone Faible malignité Fludarabine Glucocorticoïde Homme Immunomodulateur Immunothérapie Lymphome non hodgkinien Maladie résiduelle imperceptible Mitoxantrone Purine nucléotide Rituximab Réaction chaîne polymérase Stade avancé Surveillance Temps réel Traitement associé Antigène CD20 Biologie moléculaire Hémopathie maligne Lymphoprolifératif syndrome
Keyword (en)
Alkylating agent Anthraquinone derivatives Antineoplastic agent Monoclonal antibody Anticytokine Antimetabolic Drug combination Chemotherapy Corticosteroid Dexamethasone Low malignancy Fludarabine Glucocorticoid Human Immunomodulator Immunotherapy Non Hodgkin lymphoma Minimal residual disease Mitoxantrone Purine nucleotide Rituximab Polymerase chain reaction Advanced stage Surveillance Real time Combined treatment Molecular biology Malignant hemopathy Lymphoproliferative syndrome
Keyword (es)
Agente alquilante Antraquinona derivado Anticanceroso Anticuerpo monoclonal Anticitoquina Antimetabólito Asociación medicamentosa Quimioterapia Corticoesteroide Dexametasona Malignidad baja Fludarabina Glucocorticoide Hombre Inmunomodulador Inmunoterapia Linfoma no Hodgkin Enfermedad residual imperceptible Mitoxantrona Purina nucleótido Rituximab Reacción cadena polimerasa Estadio avanzado Vigilancia Tiempo real Tratamiento asociado Biología molecular Hemopatía maligna Linfoproliferativo síndrome
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R04 Combined treatments (chemotherapy of immunotherapy associated with an other treatment)

Discipline
Pharmacological treatments
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
13512079

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Searching the Web